• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Ginkgo Bioworks Holdings Inc.

    2/28/25 9:36:47 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DNA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001882820
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Ginkgo Bioworks Holdings, Inc.
    SEC File Number
    001-40097
    Address of Issuer
    27 DRYDOCK AVENUE
    8TH FLOOR
    BOSTON
    MASSACHUSETTS
    02210
    Phone
    (877) 442-5362
    Name of Person for Whose Account the Securities are To Be Sold
    Che Austin
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Class A
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    99828.634580849902/28/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Class A10/25/2022Restricted Stock VestingIssuerCheckbox not checked9910/25/2022Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A11/29/202499831.60
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/02/202499871.20
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/03/202499941.49
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/04/202499961.29
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/05/2024991019.70
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/06/202499970.20
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/09/2024991178.10
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/10/2024991085.04
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/11/2024991118.70
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/12/2024991027.62
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/13/2024991017.72
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/16/202499925.65
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/17/202499922.68
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/18/202499966.24
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/19/202499898.92
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/20/202499833.58
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/23/202499995.94
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/24/202499936.54
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/26/202499897.93
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/27/2024991013.76
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/30/202499921.69
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A12/31/202499943.47
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/02/202599987.03
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/03/2025991010.79
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/06/2025991158.30
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/07/2025991165.23
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/08/2025991070.19
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/10/2025991067.22
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/13/202599924.66
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/14/202599883.08
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/15/202599905.85
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/16/202599920.70
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/17/2025991020.69
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/21/2025991089.99
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/22/2025991153.35
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/23/2025991237.50
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/24/2025991340.46
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/27/2025991215.72
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/28/2025991184.04
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/29/2025991214.73
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/30/2025991232.55
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A01/31/2025991393.92
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/03/2025991224.63
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/04/2025991315.71
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/05/2025991414.71
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/06/2025991664.19
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/07/2025991377.09
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/10/2025991445.40
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/11/2025991310.76
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/12/2025991174.14
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/13/2025991255.32
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/14/2025991386.00
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/18/2025991513.71
    Austin Che
    27 Drydock Avenue, 8th Floor
    Boston � MA � 02210
    Class A02/19/2025991344.42
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/20/2025991237.50
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/21/2025991158.30
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/24/2025991064.25
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/25/2025991029.60
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/26/202599891.00
    Austin Che
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A02/27/202599916.74

    144: Remarks and Signature

    Remarks
    Date of Notice
    02/28/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    03/14/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Eric Janiak, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Austin Che

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $DNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNA

    DatePrice TargetRatingAnalyst
    5/15/2024Neutral → Sell
    BTIG Research
    5/10/2024Mkt Perform → Underperform
    William Blair
    11/14/2023$3.50 → $2.50Outperform → Mkt Perform
    Raymond James
    11/9/2023Buy → Neutral
    BTIG Research
    6/2/2023$3.00 → $1.25Neutral → Sell
    Goldman
    5/11/2023Outperform → Mkt Perform
    William Blair
    11/29/2022$6.00Buy
    Berenberg
    10/4/2022$5.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $DNA
    Financials

    Live finance-specific insights

    See more
    • Ginkgo Bioworks Reports First Quarter 2025 Financial Results

      Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON, May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investo

      5/6/25 5:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks Announces Date of First Quarter 2025 Results Presentation

      Presentation and Q&A session scheduled for post-market on Tuesday, May 6, 2025 BOSTON, April 29, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2025, on Tuesday, May 6, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobiowor

      4/29/25 4:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results

      Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023 BOSTON, Feb. 25, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2024. The update, including a webcast slide presentation with additional details on the fourth quarter and full year, as well as supplemental financial

      2/25/25 5:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan

      Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON, May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with key Japanese businesses and encourage the use of synthetic biology to develop sustainable production processes.

      5/14/24 6:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service

      Ginkgo customers will now have access to IdeeLab's local strain discovery capabilities, as well as the ability to manufacture next-generation products in IdeeLab's manufacturing facilities PIRACICABA, Brazil, April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, to join the Ginkgo Technology Network. The Ginkgo Technology Netw

      4/8/24 7:00:00 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world

      The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric's global network  BOSTON and SAN DIEGO, Jan. 15, 2024 /PRNewswire/ -- Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally.

      1/15/24 7:00:00 AM ET
      $DNA
      $ILMN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities

    $DNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Twist Bioscience and Ginkgo Bioworks Revise Collaboration

      New terms provide Twist with key license to long DNA technology and assets Ginkgo to continue ordering from Twist with no purchase minimums Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508352416/en/ Under the terms of the revised three-year $15

      5/8/25 8:00:00 AM ET
      $DNA
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks Reports First Quarter 2025 Financial Results

      Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON, May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investo

      5/6/25 5:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Phytolon and Ginkgo Bioworks Boost Natural Food Colors by Hitting Full-Project Milestone, Nearly Tripling the Manufacturing Efficiency of Phytolon's Innovative Colors

      Replacing artificial dyes with natural colors has become a national priority, moved by consumer demand, regulation, and governmental pressure.Achieving this milestone—by increasing coloring efficiency and reducing costs—could unlock new market segments that are not well-supported by current natural food colors.The achievement grants Ginkgo with additional equity in Phytolon, and paves the way to explore further collaborations in the field of natural food colors.YOKNE'AM ILLIT, Israel and BOSTON, April 30, 2025 /PRNewswire/ -- Phytolon, a biotech-foodtech startup that offers natural food colors via fermentation of baker's yeast, and Ginkgo Bioworks (NYSE:DNA, ", Ginkgo", )), which is building

      4/30/25 9:00:00 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sankar Shyam bought $514,750 worth of shares (625,000 units at $0.82), increasing direct ownership by 36% to 2,356,874 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      5/16/24 5:08:50 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sloan Harry bought $271,815 worth of shares (297,619 units at $0.91), increasing direct ownership by 71% to 718,540 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      5/14/24 5:16:23 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Coen Steven P. sold $7,261 worth of shares (997 units at $7.28) and converted options into 1,804 shares, increasing direct ownership by 10% to 8,819 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      4/23/25 5:03:07 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Dmytruk Mark E. converted options into 2,548 shares and sold $9,060 worth of shares (1,244 units at $7.28), increasing direct ownership by 3% to 45,453 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      4/23/25 5:00:57 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Dmytruk Mark E. converted options into 9,497 shares, increasing direct ownership by 27% to 44,149 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      3/17/25 4:32:07 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.

      10-Q - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

      5/6/25 5:04:29 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

      5/6/25 5:03:15 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Ginkgo Bioworks Holdings Inc.

      144 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

      5/6/25 9:41:25 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ginkgo Bioworks downgraded by BTIG Research

      BTIG Research downgraded Ginkgo Bioworks from Neutral to Sell

      5/15/24 7:33:13 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks downgraded by William Blair

      William Blair downgraded Ginkgo Bioworks from Mkt Perform to Underperform

      5/10/24 7:33:29 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks downgraded by Raymond James with a new price target

      Raymond James downgraded Ginkgo Bioworks from Outperform to Mkt Perform and set a new price target of $2.50 from $3.50 previously

      11/14/23 9:04:22 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

      SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

      11/14/24 4:31:49 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

      SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

      11/12/24 3:58:52 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

      SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

      11/4/24 11:56:06 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care